Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor
Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to antibodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.
1. A monoclonal human-derived anti-transthyretin (TTR) recombinant antibody or an antigen-binding fragment thereof, wherein the antibody is capable of binding mutated, misfolded, misassembled, or aggregated TTR species and/or fragments thereof and does not substantially recognize physiological TTR species, wherein the antibody or antigen-binding fragment thereof is capable of binding a TTR epitope which comprises the amino acid sequence WEPFA (SEQ ID NO: 51) and
wherein the antibody or antigen-binding fragment thereof comprises V H and V L variable regions comprising: the V H chain region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 10 and the V L chain region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 12; and wherein the complementarity determining regions (CDRs) of said V H and V L polypeptides are:
CDR-H1 comprising the amino acid sequence of SEQ ID NO: 104,
CDR-H2 comprising the amino acid sequence of SEQ ID NO: 105,
CDR-H3 comprising the amino acid sequence of SEQ ID NO: 106,
CDR-L1 comprising the amino acid sequence of SEQ ID NO: 107,
CDR-L2 comprising the amino acid sequence of SEQ ID NO: 108, and
CDR-L3 comprising the amino acid sequence of SEQ ID NO: 109; and
wherein the antibody or antigen-binding fragment thereof further comprises a polypeptide sequence which is heterologous to the V H region or V L region.
2. The antibody or antigen-binding fragment thereof of claim 1 , which binds the TTR epitope WEPFA (SEQ ID NO: 51) but not a corresponding E42G mutant epitope.
3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises the V H region amino acid sequence of SEQ ID NO: 10 and the V L region amino acid sequence of SEQ ID NO: 12.
4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is capable of binding mutated, misfolded, misassembled, and aggregated TTR species, and/or fragments thereof.
5. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof further comprises
(i) a polypeptide sequence which is heterologous to the V H region and V L region and
(ii) a heavy chain constant domain that is a human constant domain or a constant domain of the IgG type.
6. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof further comprises a heavy chain constant domain that is a human constant domain of the IgG type.
7. The antibody or antigen-binding fragment thereof of claim 1 , wherein the polypeptide sequence comprises a constant domain.
8. The antibody or antigen-binding fragment thereof of claim 7 , wherein the constant domain is a human constant domain or a constant domain of the IgG type.
9. The antibody or antigen-binding fragment thereof of claim 1 , which is:
(i) a chimeric murine-human or a murinized antibody; or
(ii) an antibody fragment selected from the group consisting of a single chain Fv fragment (scFv), an F(ab′) fragment, an F(ab) fragment, and an F(ab′) 2 fragment.
10. The antibody or antigen-binding fragment thereof of claim 1 , which is attached to a drug.
11. The antibody or antigen-binding fragment thereof of claim 1 , which comprises a detectable label selected from the group consisting of an enzyme, a radioisotope, a fluorophore, and a heavy metal.
12. A monoclonal human-derived anti-transthyretin (TTR) recombinant antibody or an antigen-binding fragment thereof, wherein the antibody is capable of binding mutated, misfolded, misassembled, or aggregated TTR species and/or fragments thereof and does not substantially recognize physiological TTR species, wherein the antibody or antigen-binding fragment thereof is capable of binding a TTR epitope which comprises the amino acid sequence WEPFA (SEQ ID NO: 51) and wherein the antibody or antigen-binding fragment thereof comprises V H and V L variable regions comprising: the V H chain region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 53 and the V L chain region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 12; and wherein the CDRs of said V H and V L polypeptides are:
CDR-H1 comprising the amino acid sequence of SEQ ID NO: 104,
CDR-H2 comprising the amino acid sequence of SEQ ID NO: 105,
CDR-H3 comprising the amino acid sequence of SEQ ID NO: 106,
CDR-L1 comprising the amino acid sequence of SEQ ID NO: 107,
CDR-L2 comprising the amino acid sequence of SEQ ID NO: 108, and
CDR-L3 comprising the amino acid sequence of SEQ ID NO: 109; and
wherein the antibody or antigen-binding fragment thereof further comprises a polypeptide sequence which is heterologous to the V H region or V L region.
13. The antibody or antigen-binding fragment thereof of claim 12 , which binds the TTR epitope WEPFA (SEQ ID NO: 51) but not a corresponding E42G mutant epitope.
14. The antibody or antigen-binding fragment thereof of claim 12 , wherein the antibody or antigen-binding fragment thereof comprises the V H region amino acid sequence of SEQ ID NO: 53 and the V L region amino acid sequence of SEQ ID NO: 12.
15. The antibody or antigen-binding fragment thereof of claim 12 , wherein the polypeptide sequence comprises a constant domain.
16. The antibody or antigen-binding fragment thereof of claim 15 , wherein the constant domain is a human constant domain or a constant domain of the IgG type.
17. The antibody or antigen-binding fragment thereof of claim 12 , which is:
(i) a chimeric murine-human or a murinized antibody; or
(ii) an antibody fragment selected from the group consisting of a single chain Fv fragment (scFv), an F(ab′) fragment, an F(ab) fragment, and an F(ab′) 2 fragment.
18. The antibody or antigen-binding fragment thereof of claim 12 , which is attached to a drug.
19. The antibody or antigen-binding fragment thereof of claim 12 , which comprises a detectable label selected from the group consisting of an enzyme, a radioisotope, a fluorophore, and a heavy metal.
20. The antibody or antigen-binding fragment thereof of claim 12 , wherein the antibody is capable of binding mutated, misfolded, misassembled, and aggregated TTR species, and/or fragments thereof.
21. The antibody or antigen-binding fragment thereof of claim 12 , wherein the amino acid sequence at the N- and/or C-terminus of the V H and/or V L chain contains amino acids which have been replaced by primer-induced mutation correction.
22. The antibody or antigen-binding fragment thereof of claim 12 , wherein the polypeptide sequence is heterologous to the V H region and the V L region.